Clareo Health | Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers
Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
16–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Any patient with diagnosis of SCD based on high-performance liquid chromatography (HPLC) or hemoglobin electrophoresis at treating institution
Treatment order for crizanlizumab; Index date was defined as the date for the first crizanlizumab treatment
At least 12 months of available electronic medical record (EMR) data pre-index date (baseline)
Patients must have received at least one dose of crizanlizumab
For inclusion in pre/post analysis of effectiveness, patients must have received at least 6 doses of medication. The rates could be annualized if total post-index time was \<12 months.
